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Sincefirst introduced in themid-1960s, coronaryarterybypass grafting (CABG)hasbecomethe standardof care forpatientswith coronaryartery
disease. Surprisingly, the fundamental surgical technique itself did not changemuch over time.Nevertheless, outcomes afterCABGhave dramat-
ically improved over the first 50 years. Randomized trials comparing percutaneous coronary intervention (PCI) toCABGhave shownconverging
outcomes for select patient populations, providingmore evidence forwider use of PCI. It is increasingly important to focus on the optimization of
the short- and long-termoutcomes of CABGand to reduce the level of invasiveness of this procedure. This reviewprovides an overview on how
new techniques and widespread consideration of evolving strategies have the potential to optimize outcomes after CABG. Such developments
include off-pumpCABG, clampless/anaortic CABG, minimally invasive CABGwith or without extending to hybrid procedures, arterial revascu-
larization, endoscopic vein harvesting, intraprocedural epiaortic scanning, graft flow assessment, and improved secondary prevention measures.
In addition, this review represents a framework for future studies by summarizing the areas that needmore rigorous clinical (randomized) evalu-
ation.
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Introduction
Coronary artery bypass grafting (CABG) was first introduced in the
mid-1960s and evolved rapidly as the standard of care for patients
with extensive coronary artery disease.1 However, the introduction
of percutaneous coronary intervention (PCI) led to a reconsider-
ation of therapeutic strategies.2 Improvements in stent design, adju-
vant medical therapy and technical skills quickly turned PCI into a
very attractive alternative treatment option for patients with acute
coronary syndromes and less complex coronary disease.3–7 The
broader use of PCI is reflected by declining CABG rates over the
last decades,8 even though recent long-term results from the
SYNTAX,9 ASCERT,10 and FREEDOM11 trials showed significantly
better survival rates after CABG than after PCI. Despite converging
outcomes between the two treatments in select patient populations,
coronary surgery currently remains the standard of care for most
elective patients, including those with diabetes and/or complex left
main or three-vessel disease.9,12
Although short-term outcomes have dramatically improved over
the first 50 years, surprisingly, technical aspects of theCABGproced-
ure did not change significantly. Particularly in an era of increasing and
sometimes overuse of PCI, several aspects of CABG should be
improved to further optimize short- and long-term outcomes,
while at the same time improving the appeal of CABG which is
regarded as an overly invasive attractive treatment option by some.
A number of advancements have been proposed, but adoption
rates for these techniques are low.
This review provides a summary of how CABG outcomes can be
optimized by adoption of new developments. These developments
include off-pump, clampless/anaortic, and minimally invasive CABG
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withorwithout extending tohybridprocedures, arterial revasculariza-
tion, endoscopic vein harvesting, intraprocedural epiaortic scanning
and graft flow assessment and improved secondary prevention mea-
sures. Furthermore, this review represents a framework for future
studies by summarizing the areas that need more rigorous clinical
evaluation.
Operative techniques
Off-pump surgery
In 2001,25%of CABGprocedureswere performed off-pump.13 In
theWestern world, the contemporary rate of off-pump CABG pro-
cedures is 20%, while in Asia the majority of procedures is per-
formed off-pump.14 Theoretically off-pump CABG could reduce
morbidity—particularly stroke—and evenmortality by avoiding car-
diopulmonary bypass that is associated with formation of microem-
boli, an increased blood–brain barrier permeability and aortic
manipulation during cross-clamping and cannulation.15
Numerous risk-adjusted studies have found that the off-pump
technique appears favourable in terms of both hard and surrogate
endpoints.16,17 A meta-analysis of propensity score-adjusted
studies that included.120 000 patients demonstrated the superior-
ity of the off-pump techniquewith respect to 11 selected short-term
outcomes, particularly for mortality as the most important one
(OR ¼ 0.69; 95% CI: 0.60–0.75; P, 0.0001) and for stroke (OR ¼
0.42; 95% CI: 0.33–0.54; P, 0.0001).18 In addition, the most
recent meta-analysis of 59 randomized trials on a total of 8961
patients comparing on-pump with off-pump CABG demonstrated
a 30% (95% CI: 1–51%) relative risk reduction for stroke.13
However, some studies have shown increased rates of mortality and
repeat revascularization during the follow-up;19,20 probably caused
by reduced graft patency after off-pump vs. on-pump CABG.21,22
Although single-centre prospective angiographic studies have
shown similar excellent graft patency rates with off-pump and
on-pump CABG,23 the 1-year results from the ROOBY trial
showed a 27% higher risk of graft occlusion in the off-pump group
(95% CI: 9–48%); graft patency was 87.8% in the on-pump and
82.6% in the off-pump patients (P, 0.001).24 These results were
criticized for the lack of sufficient experience that contributing
surgeons had with off-pump procedures.25 However, several other
trials involving highly experienced surgeons and a meta-analysis
pointed in a similar direction as the findings from the ROOBY
trial.25–27 Off-pump CABG has also been associated with increased
rates of incomplete revascularization, and could result in reduced
long-term survival.28
The CORONARY trial showed no benefit of off-pump CABG
over on-pump CABG at 30 days or 1 year in 4752 randomized
patients.29,30 Although there appears to be a significant benefit of
off-pump over on-pump CABG in patients at high-operative risk31
and in patients with atherosclerotic aortas,32 the hypothesis that
off-pumpCABG is beneficial for ‘all-comers’maybe toooptimistic.33
Despite the encouragement to a general use of off-pump techniques,
it has been recommended specifically for high-risk patients.34
However, even this recommendation was recently challenged by
the results of the GOPCABE trial, which did include elderly higher-
risk patients (n ¼ 2539) but was still unable to confirm superiority
of the off-pump over the on-pump approach in this subset of
patients.35 Patient selection is critical, since the majority of patients
can safely and efficiently undergo on-pump CABG without the risk
of increased 30-day repeat revascularization rates associated with
off-pump procedures in the latest trials.29,30,35 It may therefore be
cumbersome for trainees to gain experience in a procedure with a
steep learning curve that is infrequently performed only in selected
patients.
It is worth noting that although evidence for a survival benefit of
off-pump CABG is inconsistent across the peer-reviewed literature,
a preponderance of evidence suggests that it is associated with
significant reductions in transfusion requirements, prolonged ven-
tilation, ICU and hospital length of stay, new renal failure, stroke/
neurocognitive decline and other clinical endpoints.36
Clampless/anaortic off-pump surgery
If off-pump CABG is performed, the degree of aortic manipulation
should be reduced to a minimum. The benefit of off-pump CABG
may be limited unless partial clamping of the aorta is avoided.
Aortic clamping produces a significantly higher number of solid
microemboli on transcranial Doppler than clampless surgery and
can therefore lead to procedural stroke.37 It is to note that in most
trials, including the major randomized trials, off-pump CABG was
not performed using an anaortic technique, the major driver for re-
ducing stroke.
Thenumberof studies that comparedclamplessCABGto ‘regular’
CABGwith clamping is limited (Table 1). In the absence of a large ran-
domized comparison, Bo¨rgermann et al.38 used propensity matching
to comparemortality and stroke rates between patients who under-
went clampless off-pump or conventional CABG. In the propensity-
matched cohort of 395 pairs, clampless off-pump CABG reduced
rates of death (OR ¼ 0.25, 95% CI: 0.05–1.18; P ¼ 0.080) and
stroke (OR ¼ 0.36, 95%CI: 0.13–0.99; P ¼ 0.048).More specifically,
one of the largest studies to date found significantly lower stroke
rates after off-pump than on-pump CABG, if an all-arterial ‘no
touch’ technique was applied or when the proximal vein-graft anas-
tomoses were performed clampless using the HeartString device
(Guidant, Indianapolis, USA).39 This evidence is complemented by
a meta-analysis including 11 398 patients that showed that the
absence of aortic manipulation was associated with a significant re-
duction of neurological complications (OR ¼ 0.46, 95% CI: 0.29–
0.72; P ¼ 0.0008).40
Minimally invasive coronary artery bypass
grafting/hybrid revascularization
One of the drawbacks of CABG remains its invasiveness, even
without the use of cardiopulmonary bypass. Quality of life scores
at 30 days and patient treatment satisfaction surveys throughout
the first 6 months are significantly higher after PCI than after
CABG.41 Moreover, CABG is sometimes referred to as a procedure
where ‘the chest is cracked open’, which from a patient’s perspective
presents a frightening prospect of postoperative pain and extended
rehabilitation. As a result, patients often prefer PCI to CABG
because of ‘temporal discounting’, i.e. disproportionally emphasize
short-term results even though CABG has been shown to be super-
ior to PCIwith respect to long-term survival and angina relief.10,41–44
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Table 1 Studies comparing clampless or ‘aortic no touch’ off-pump coronary artery bypass grafting with conventional off-pump or on-pump surgery
Author (year) Inclusion Design No. of patients Use of devices Unadjusted 30-day outcomes Comment
Mortality Stroke Perioperative
MI
Clampless
Lev-Ran (2004) 2000–02 Retrospective 103 vs. 57 with clamp No 2.9 vs. 7% 0 vs. 5.3% 3 vs. 5% Side clamping an independent predictor of stroke or
mortality: OR ¼ 6.28, 95% CI: 1.39–28.4; P ¼ 0.017
Kempfert (2008) 2003–05 RCT 51 vs. 48 with clamp Connector: PAS-Port 0 vs. 2.1% — —
Manabe (2009) 2004–07 Retrospective 109 vs. 185 no touch
vs. 241 with clamp
HeartString (n ¼ 81)
Enclose II (n ¼ 28)
1.8 vs. 1.1
vs. 1.2%
2.8 vs. 0.5 vs.
0.8%
—
El Zayat (2012) 2009 RCT 29 vs. 28 with clamp HeartString 0 vs. 0% 0 vs. 6.9% —
Emmert (2012) 1999–2009 Prospective 507 vs. 524 with clamp HeartString 1.8 vs. 2.5% 0.4 vs. 2.9% 1.5 vs. 3.1% Clampless off-pump CABGwas a significant predictor of
reduced stroke in a propensity-score-adjusted
analysis: OR ¼ 0.04, 95% CI: 0.003–0.48
Bo¨rgermann (2012) 2009–10 Prospective 395 vs. 887 with clamp Connector: PAS-Port
(n ¼ 310)
3.3 vs. 7.6% — — In a propensity-matched cohort of 395 pairs, clampless
off-pump CABG was a predictor of less death
(OR ¼ 0.25, 95% CI: 0.05–1.18; P ¼ 0.080) and
stroke (OR ¼ 0.36, 95% CI: 0.13–0.99; P ¼ 0.048)
Aortic no touch
Patel (2002) 1997–2001 Prospective 597 vs. 520 off-pump
with manipulation
vs. 1210 on-pump
No 1.5 vs. 1.0
vs. 2.5%
0.5 vs. 0.4 vs.
1.6%
— Aortic manipulation was not a significant predictor of
neurological outcome in off-pump patients
Calafiore (2002) 1998–2000 Retrospective 1533 vs. 3290 any
manipulation (on-
or off-pump)
No — 0.2 vs. 1.4% — In multivariable stepwise logistic regression, any aortic
manipulation was associated with an OR of 8.4 (95%
CI: 2.4–28.9; P ¼ 0.0008) for stroke
Kim (2002) 1998–2001 Prospective 222 vs. 123 ‘regular’
off-pump vs. 76
on-pump
No 0.9 vs. 2.4
vs. 2.6%
0 vs. 0.8 vs.
3.9%
1.4 vs. 5.7 vs.
6.6%
Leacche (2003) 1996–2001 Retrospective 84 vs. 556 ‘regular’
off-pump
No 1.6 vs. 1.7% 0 vs. 1% 1.3 vs. 1.8%
Kapetanakis (2004) 1998–2002 Retrospective 476 vs. 2527 moderate
vs. 4269 extensive
aortic manipulation
off-pump
No 1.5 vs. 1.9
vs. 2.1%
0.8 vs. 1.6 vs.
2.2%
1.1 vs. 0.7 vs.
0.5%
No touch surgery was independently associated with
reduced stroke when compared with extensive
(OR ¼ 1.7, 95% CI: 1.11–2.48; P, 0.01) and even
moderate aortic manipulation (OR ¼ 1.8, 95% CI:
1.15–2.74; P, 0.01). Propensity-matched analysis
failed to show similar findings
Lev-Ran (2005) 2000–03 Retrospective 471 vs. 229 off-pump
with side-clamp
No 2.1 vs. 2.6% 0.2 vs. 2.2% 1.4 vs. 1.5% Theuseof side-clampingwas an independentpredictorof
stroke: OR ¼ 28.5, 95% CI: 2.27–333.3; P ¼ 0.009
Bolotin (2007) 2000–01 Prospective 110 vs. 216 on-pump
CABG
No 2.7 vs. 1.9% 0 vs. 2.3% 0.9 vs. 1.4%
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Less invasive surgical techniques may present an attractive alterna-
tive; minimally invasive direct coronary artery bypass (MIDCAB)
does not require sternotomy and is therefore more acceptable to
patients than conventional CABG.45 The left minithoracotomy inci-
sion is smaller, the risk of scarring is less, and risks of deep sternal
wound infection and problemswith sternum healing are omitted. Al-
thoughMIDCABmay be associatedwith slightly increased pain post-
operatively due to spreading of the ribs, the length of stay ismarkedly
reduced and there is an early postoperative quality of life benefit over
conventional CABG.46–48 MIDCAB was shown to be as safe and ef-
ficient as off-pump CABG, while reducing the recovery time.49
Holzhey et al.50recently reported long-term results from their single-
centre experience on 1768 patients. Five- and 10-year survival was
88.3 and 76.6%, respectively. The rates of freedom from major
adverse cardiac or cerebrovascular events and angina were of 85.3
and 70.9%, respectively.
ExposureduringMIDCAB is largely limited to the left anterior des-
cending (LAD) artery and eventually diagonal branches, and there-
fore almost exclusively performed in patients with isolated LAD
stenosis or occlusion. An open left internal mammary artery (IMA)
graft to the LAD is without doubt the single most important
conduit thatoffers aprognosticbenefitbasedon its proven long-term
patency and improved survival. Patients with multivessel disease—
especially at youngerage—alsoderive a survival benefit from total ar-
terial graftingwith bilateral IMA (BIMA) grafts.51 The added benefit of
a second arterial graft in older patients is less well documented;52
however, the rate of early vein-graft failure, especially to distal
targets and severely diseased small vessels, is high and ranges from
10 to 26% between 12 and 18 months after surgery.21,53 In some
patients, a hybrid procedure can combine the benefits of an
MIDCAB—providing a left IMA (LIMA) graft to the LAD—and stent-
ing of the circumflex and/or the right coronary artery. This type of
managementmay yield results similar to thoseof a fullCABGproced-
ure,54 but randomized trials are still lacking (Table 2). The hospitaliza-
tion costs of hybrid revascularization are similar to the costs of
off-pump CABG, but the time to return to work is shorter and
patient satisfaction higher.55 Halkos et al.56,57 showed that survival
after hybrid revascularization at 5-year follow-up was comparable
with off-pump CABG in patients with left main disease (88.6 vs.
83.4%, respectively; P ¼ 0.55) and in patients with multivessel
disease (86.8 vs. 84.3%, respectively; P ¼ 0.61) (Figure 1).
Complete revascularization in patients with multivessel disease by
minimally invasive CABG can also be achieved via a totally endos-
copic coronary artery bypass (TECAB) procedure,58 by combining
an endoscopic with an open approach,59 or by a hybrid endoscopic
and percutaneous procedure.60 Such procedures are only per-
formed in selected patients at specialized centres and require exten-
sive operating times. Earlier series reported unsatisfactory patency
results, but with the evolution of better endoscopic stabilizers the
results from these highly experienced centres are similar to conven-
tional CABG with a reported mortality rate of 1–2% 58–61 and a
5-year survival in the range of 85–95%.60–62
Adoption of minimally invasive CABG procedures has been slow.
For MIDCAB, this may be explained in part by the low incidence of
isolated proximal LAD stenosis63 and also by the high technical
demands of this procedure. Hybrid revascularization for multivessel
disease, theoretically, has a much larger target population. However,
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a systematic search of the literature shows that the accumulated evi-
dence is based on small non-randomized studies comprising just over
1000 patients in total (Table 3). Between October 2003 and April
2010, only 174 patients underwent hybrid revascularization in the
USA.56,57 Apart from technical issues, the low-adoption rate is
partly due to logistic reasons; the staging of two procedures in a
(hybrid) operating rooms, and/or catheterization laboratory, and
the administration or discontinuation of antiplatelet therapy. A
survey performed in 2002 indicated that 80% of US surgeons
perform less than five MIDCAB procedures annually.64 When
asked about hybrid procedures, only 10% of surgeons were in
favour. In contrast, 50% of 180 cardiologists were in favour of
hybrid revascularization. Yet, only two cardiologists (1.1%) had re-
ferred patients for MIDCAB (with or without PCI). Stronger
evidence to support a recommendation for hybrid revascularization
is expected from a number of currently on-going registries, the
largest of which is the Hybrid Revascularization Observational
Study (NCT01121263) that includes patients throughout the USA
and is sponsored by the National Heart, Lung, and Blood Institute
(NHLBI).
Arterial grafting
The useof one IMAgraft,most often the left IMAanastomosed to the
LAD combined with venous conduits represents the standard
therapy for patients undergoing CABG.65,66 However, venous
bypass grafts tend to fail: a recent study by Kim et al.67 found that
11.8% of saphenous vein grafts failed within 7 days, which is similar
to the failure rate reported by FitzGibbon et al.68 Therefore, BIMA
grafting should be strongly considered in patients with multivessel
coronary disease, because BIMA grafting is associated with reduced
mortality during the first year post-surgery and during the long-term
follow-up.69 A meta-analysis of seven pooled studies with 11 269
single and 4693 bilateral IMA grafts demonstrated that BIMA was
associated with a reduced risk for death: HR ¼ 0.81 (95% CI:
0.70–0.94).51
In the Arterial Revascularization Trial (ART), the only randomized
trial to date comparing BIMA and single IMA (SIMA), 3102 patients
were randomized in 28 centres in 7 countries.70 Mortality rates at
30 days were 1.2% in both groups, and 2.3 vs. 2.5% at 1-year for
SIMA and BIMA groups, respectively. Therewere also no differences
in the incidence of stroke,MI, and repeat revascularization.While the
use of a second IMA graft added 23 min to the operative procedure
which in itself took 3–4 h, the trial clearly demonstrated that BIMA
grafting was as safe as SIMA grafting, even though the risk of a need
for later sternal reconstruction was increased: relative risk 3.24
(95% CI: 1.54–6.83). An extended follow-up (for up to 10 years) is
expected for this study andwill hopefully determinewhether survival
with BIMA grafts is indeed superior. The trial, however, also
Table 2 Reasoning supporting hybrid
revascularization
Patients with double vessel disease and chronic total occlusion of the
LAD
Patients with multivessel disease and an indication for CABG requiring
complete revascularization in whom a full sternotomy is
contraindicated or not desired
Patients with multivessel disease with a dominant LAD or complex
proximal LAD lesion morphology and poor surgical targets in the
distal CX or RCA territory amenable for PCI
Patients with multivessel disease with an indication for PCI (SYNTAX
score ,22) or in clinical trials comparing hybrid revascularization
with PCI or CABG (SYNTAX score .23)
Patients with multivessel disease undergoing emergent PCI of a culprit
lesion of a CX or RCA lesion (in the setting of STEMI, non-STEMI, or
ACS) with a staged surgical revascularization of the LAD
Figure 1 Long-term survival of hybrid revascularization in comparison with off-pump coronary artery bypass grafting. A comparison between
treatment strategies shows no differences in 5-year survival in patients with multivessel disease (A), nor in patients with left main disease (B).
Adapted with permission from Halkos et al.56,57
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Table 3 Systematic review of studies evaluating hybrid revascularization
Author (year) Inclusion Design No. of patients Type of lesions Strategy 30-day outcomes Long-term outcomes
Conversion Death Revascularization Mean follow-up Mortality Revascularization
Lloyd (1999) 1996–98 Prospective 18 Multivessel Simultaneous, n ¼ 4
PCI following MIDCAB, n ¼ 14
0 0 5.6% At 18 months 0 5.6%
Zenati (1999) 1996–98 Retrospective 31 Multivessel Staged 0 0 3.2% 11 months 0 9.6%
Wittwer (2000) 1996–99 — 35 Multivessel PCI following MIDCAB 0 0 0 11+ 8 months 0 6.5% (of 31 patients)
de Canniere (2001) 1997–97 Retrospective 20 Two-vessel MIDCAB following PCI, n ¼ 9
PCI following MIDCAB, n ¼ 11
0 0 0 At 2 years 0 15%
Cisowski (2002) 1999–2001 Retrospective 50 Two-vessel PCI following MIDCAB 0 0 0 — 0 12.7%
Riess (2002) 1997–2001 Retrospective 57 Multivessel PCI following MIDCAB 0 0 0 101+ 38 weeks 1.8% —
Stahl (2002) — Retrospective 54 Multivessel PCI following MIDCAB, n ¼ 35
MIDCAB following PCI, n ¼ 19
0 0 0 12 months 0 —
Davidavicius (2005) 2001–03 Prospective 20 Multivessel MIDCAB following PCI, n ¼ 14
PCI following MIDCAB, n ¼ 6
0 0 0 19+ 10 months 0 0
Katz (2006) — Prospective 27 Two-vessel Simultaneous, n ¼ 4
PCI following MIDCAB, n ¼ 12
MIDCAB following PCI, n ¼ 11
0 0 0 At 3 months 0 18.5%
Us (2006) 2002–04 Prospective 17 Multivessel MIDCAB following PCI 0 0 0 21+ 7 months 0 17.6%
Gilard (2007) 2000– . . . Prospective 70 Multivessel MIDCAB following PCI 0 1.4% 2.9% 33 months 1.4% 0
Holzhey (2008) 1996–2007 Retrospective 117 Multivessel Simultaneous, n ¼ 5
PCI following MIDCAB, n ¼ 59
MIDCAB following PCI, n ¼ 53
0 1.9% 1.9% 208 patient-years 92.5% at 1 year
84.8% at 5 years
—
Kiaii (2008) 2004–07 Prospective 58 Two-vessel Simultaneous 1.7% 0 0 20 months 0 —
Kon (2008) 2005–06 Prospective 15 Multivessel Simultaneous 0 0 0 At 1 year 0 6.7%
Gao (2009) 2007–08 Prospective 10 Multivessel PCI following MIDCAB 0 0 0 5 months 0 0
Vassiliades (2009) 2003–07 Prospective 91 Multivessel Staged 2.0% 0 0 — 94% at 3 years 5.5% at 1 year
Zhao (2009) 2005–07 Retrospective 112 Multivessel Simultaneous N/A 2.6% 0 — — —
Delhaye (2010) 2006–08 Prospective 18 Multivessel PCI following MIDCAB 0 0 0 At 1 year 0 5.6% (TVR)
Halkos (2011) 2003–10 Retrospective 27 LM PCI following MIDCAB 0 0 0 Median 3.2 years 88.6% at 5 years 7.4%
Halkos (2011) 2003–10 Retrospective 147 Multivessel Simultaneous n , 10
Staged for the remaining
0 0.7% 0 Median 3.2 years 86.8% at 5 years 12.2%
8.8% (TVR)
Hu (2011) 2007–09 Retrospective 104 Multivessel Simultaneous 1.0% 0 0 18 months 0 1.9%
Rab (2012) 2003– . . . Retrospective 22 LM PCI following MIDCAB 0 0 0 39+ 23 4.5% 0
The PubMed database was searched from its inception through June 2012, which yielded the included studies.
CABG, coronary artery bypass grafting; MIDCAB, minimally invasive coronary artery bypass; N/A, not applicable; LM, left main; PCI, percutaneous coronary intervention; TVR, target vessel revascularization. S.J.H
ead
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highlighted the difficulties with BIMA grafting; 16.4% of patients ran-
domized to BIMA did not receive the allocated treatment compared
with 3.3% patients not receiving SIMA grafting.71
The proportion of procedures that are performedwith IMA grafts
is increasing, but a large inter-hospital variance remains. The use of at
least one IMA can be as low as 45–65% in some centres, failing to
provide optimal care to patients.72 It is disconcerting that in the
USA the use of BIMA grafts was only 4.0% among 541 368 patients.72
The respective figures are 12% in Europe and 30% in Japan.73 Among
1541 procedures performed in the SYNTAX trial and registry,
97.1% included a single arterial conduit while 22.7% received a
second IMA graft. Owing to the technically more challenging and
time-consuming nature of BIMA grafting, the fear of highermorbidity
(i.e. sternal wound complications) and mortality, and the absence of
clear randomizeddata showing a survival benefit, some surgeonsmay
be reluctant to use BIMA grafts. Nevertheless, in order to improve
CABG outcomes, the use of both IMA grafts should be considered
more frequently.
Whenunilateral IMAgrafting isperformed, the saphenousvein is the
most frequently chosen conduit for additional graft(s). Because of high
failure rates of venous grafts, the radial artery has been investigated as
analternative.The long-termresults fromtheRSVPtrial (n ¼ 142) sug-
gested favourable radial artery graft patency rates.74 More recent
5-year results from the larger randomized RAPS trial (n ¼ 510)
showed that, compared with the saphenous vein grafts, the radial
artery had lower rates of functional graft occlusion (12.0 vs. 19.7%, re-
spectively; P ¼ 0.03) and complete occlusion (8.9 vs. 18.6%, respect-
ively; P ¼ 0.002), although the string sign was observed more
frequently in radial artery grafts (3.4 vs. 0%, P ¼ 0.01).75 Several large
observational studies have confirmed excellent graft patency and
haveevenreportedsuperior long-termsurvival rates,76,77alsoafterap-
plying propensity matching.78–80 However, widespread utilization of
the radial artery has been hampered by concerns regarding vessel
spasm, graft atherosclerosis, and unfavourable results from a number
of studies. The largest trial (n ¼ 733) to date found no differences in
graft patency at 1-year follow-up;81 similar results have been reported
from a number of observational studies.79,82 At least one study has
shown radial artery graft patency to be significantly worse than right
IMA graft patency.83 To ensure good graft patency, the radial artery
should be used preferably in high-grade lesions.84 Data from the STS
database suggest that only 9% of CABG procedures are performed
with the radial artery.85
A higher rate of disease progression to total occlusion in native
coronaries has been reported afterCABGthan afterPCI.86 Patent ar-
terial grafts, by virtue of their nitric oxide secreting properties, may
protect against future atherosclerotic lesions. Therefore, arterial
grafting can be viewed as a preventive measure that goes beyond
pure treatment.87,88
Endoscopic vein harvesting
Traditional open saphenous vein-graft harvesting requires a large in-
cision, resulting in a large scar and a riskof postoperativewound com-
plications. Endoscopic vein harvesting was introduced in the
mid-1990s as an alternative.89 This method has the advantages of
reduced scarring, less pain, decreased postoperative complications,
and shorter length of stay.90
Several randomized studies and meta-analyses have shown that
endoscopic harvesting significantly reduces rates of wound infection,
wound dehiscence, and overall complications.91 However, subgroup
analyses from the PREVENT IV and ROOBY randomized trials sug-
gested that endoscopic vein harvesting resulted in reduced graft
patency during the follow-up.92,93 In PREVENT IV, there even were
significantly higher rates of death. Although this is of potential
concern, long-term follow-up analyses from large observational
studies have not been able to confirm that clinical outcomes are
worse in patients that underwent endoscopic vein harvesting.94,95
A recent study that included 235 394 patients with 3-year follow-up
showed no increased risk of mortality [adjusted HR ¼ 1.00 (95% CI:
0.97–1.04) P, 0.99] or the composite of mortality, myocardial in-
farction, and repeat revascularization [adjusted HR ¼ 1.00 (95% CI:
0.98–1.05) P ¼ 0.34].95
Current data indicate a paradigm shift towards endoscopic harvest-
ing as opposed to open vein graft harvesting. Between 2003 and 2008,
52%of grafts were harvested endoscopically at 989 sites in theUSA; in
2008, the ratewas already 70%.95 Trainees in theUSA nowalmost ex-
clusively learn how toperformendoscopic harvesting.90 It is important
to start using this technique at an early stage, especially because inex-
perienced surgeons are known to cause significantly more vein
injury.96The InternationalSocietyofMinimally InvasiveCardiothoracic
SurgeryConsensusstatementhasgivenaClass IBrecommendation for
endoscopic veinharvesting.97 Still, endoscopic harvesting is performed
in only a minority of cases in Europe. A recent single-centre study
showed that only 12.4% of veins were harvested endoscopically
between 2008 and 2010.98 Unfortunately, large-scale real-world
data from European centres are scarce.
Intra-operative assessments
Epiaortic scanning
Atherosclerosis of the ascending aorta is present in.50% of patients
undergoing CABG.99 Aortic atherosclerosis was found to be a signifi-
cant predictor of postoperative neurological events and renal failure,
both caused by atheroembolism.100,101 Palpation of the aorta is fre-
quently employed prior to cannulation and/or aortic manipulation,
but the sensitivity of this technique is very limited.102 Therefore,
imaging is advocated to detect atherosclerosis if an anaortic technique
cannot be applied.Depending on the findings, the operative technique
can be modified as needed.103 Both transoesophageal echocardio-
graphy and epiaortic ultrasonography were introduced as methods
for detecting severe atherosclerosis. While transoesophageal echo-
cardiography severely underestimates the degree of atherosclerosis,
epiaortic scanning is an easy, safe and efficient procedure and is pre-
ferred.104
Epiaortic scanning is not routinely used probably because of the
cost of the machine (.E100 000) and the fact that there have
been no direct randomized comparisons between CABG with and
without epiaortic scanning that demonstrate a benefit. Such a study
would be problematic because of the large sample size required.
However, although one small study indicated no reduction in tran-
scranial Doppler-detected cerebral emboli,105 several studies have
suggested that early postoperative stroke is significantly reduced
when the operative technique is modified in accordance with
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results of epiaortic scanning.106–109Wareing et al.110 reported that in
14% of elderly patients undergoing cardiac procedures (CABG in
89%), the site of aortic cannulation and/or clamping, the sites for
attaching vein grafts, and/or the sites for instillationof cardioplegic so-
lutionwere altered. The precise rates of suchmodifications provided
in the literature vary, between 4 and 31%.99 A recent study byDaniel
et al.111 showed that epiaortic scanning was increasingly performed
from 2002 to 2009 (45 and 90%, respectively) and coincided with
less frequent aortic clamping (98 and 73%, respectively).
Graft flow measurement
Data from the PREVENT IV trial showed a suboptimal rate of saphe-
nous vein-graft failure after on- and off-pump CABG at 1 year;112 a
meta-analysis reported a failure rate of 5 and 25% at 3 and 12
months, respectively.113 Several mechanisms of graft failure have
beendescribed. Early graft failure canoccur as a result of anastomotic
problems, limited outflow, graft kinking upon chest closure, and
thrombosis. Late failure is the result of thrombosis and processes
of intimal hyperplasia and atherosclerosis. Intra-operative graft as-
sessment has been introduced to evaluate grafts and identify anasto-
motic problems and limited outflow. Disturbingly, Balacumaraswami
et al.114 demonstrated that intra-operativegraft assessment identified
9%of graftswith inadequate flow in 25%ofCABGpatients, which led
to revision in 3% of grafts and 8% of patients. Multiple techniques for
intra-operative graft assessment have been proposed: coronary
angiography, transit time flowmeasurement (TTFM), high-frequency
epicardial echocardiography, thermal coronary angiography and
intra-operative fluorescence imaging (IFI).115 Although angiography
is thought to be the best and most reliable method for assessing
flow,116 the infrastructure required for coronary angiography is
rarely available in standard operating rooms. Wider implementation
of hybrid operating rooms could potentially facilitate the use of cor-
onary angiography. Currently, intra-operative graft assessment is
most frequently performed by TTFM or IFI.
Both TTFM and IFI have strengths and weaknesses and have been
criticized for their inability to identify graftswithminor abnormalities
that present a risk for failure. Furthermore, inconsistent and variable
measurementsmay lead to unnecessary graft revisions.114 Twopara-
meters, graft function and anatomy, are required for the complete as-
sessment of bypass grafts. Transit time flow measurement assesses
function and can very accurately detect truly poor and truly good
grafts (true positives, true negatives), but there is an issue with
respect to detecting poor grafts with a low pulsatility index (PI)
(false negatives). False positives (good graft, high PI) rarely occur.
Intra-operative fluorescence imaging evaluates anatomy but is asso-
ciated with more inter-observer error than standard angiography.
Comparisons between TTFM and IFI suggest that IFI is more
sensitive.113,114,117 Transit time flow measurement combined with
epicardial ultrasonic scanning is a recently introduced approach
that may provide both a functional as well as anatomic assessment.
Despite issues, the clinical value of TTFM has been demonstrated
in studies that found that TTFM predicted graft failure at 3, 6, and/or
12months post-CABG.118–120 Inadequate graft flowas defined by PI
.5 on TTFM was found to be an independent predictor of major
adverse cardiac events, operative death in particular.121 No studies
have yet explored the impact of IFI measurements on clinical out-
comes during the follow-up. In general, randomized comparisons
between CABG with and without graft flow measurement remain
absent. Such studies would be required to evaluate the true benefit
their routine intra-operative use would have on early and late rates
of reintervention, myocardial infarction and death. One issue that
remains, however, is that long-term graft failure would still occur
as caused by other mechanisms than those controlled by intra-
operative graft assessment. This could beoneof the reasonswhy sur-
geons doubt its clinical impact and consequently why routine use has
been limited.
Secondary prevention
Apart from technical and procedural considerations, further optimiza-
tion of long-term outcomes after CABG can be achieved through a
strict medical regimen. Progression of atherosclerosis in the native
coronary arteries continues after CABG and is associated with
deterioration of left ventricular function. However, this can be pre-
vented by the administration of antiplatelet agents,122 b-blockers,123
angiotensin-converting enzyme inhibitors (ACE-I),124 statins125,126
and fatty acids,127 all ofwhich have been identified as independent pre-
dictors of survival after CABG. The PREVENT IV trial found that sec-
ondary prevention medications were associated with significantly
reduced rates of death ormyocardial infarction after CABG.128More-
over, data suggest that graft patency may be better in patients taking
statins,129 fatty acids,130 aspirin,65 and possibly dual antiplatelet
therapy.131 Administration of secondary prevention medications has
increased remarkably,132,133 and differences between PCI and CABG
have shown to converge (Table 4). Nevertheless, some data have
shown that differences between PCI and CABG still remain and
again stressed the need for further progress (Figure 2).134–136
Furthermore, theeffect of lifestyle interventionsonoutcomesmay
be underestimated.A plethoraof data exists on the impact of lifestyle
intervention on outcomes after CABG. Van Domburg et al.,137 for
example, reported that patients who quit smoking had signifi-
cantly improved 30-year survival when compared with persistent
smokers after CABG [HR ¼ 0.60 (95% CI: 0.48–0.72)]. Education
and counselling on eliminating risk factors, healthy food choices,
stress relief and exercise provide substantial benefit for patients.138
A meta-analysis that combined 63 randomized clinical trials with
follow-up data on 21 295 patients found that implementation of sec-
ondary prevention programmes significantly reduced all-cause mor-
tality [risk ratio (RR) ¼ 0.85 (95% CI: 0.77–0.94)] and myocardial
infarction [RR ¼ 0.83 (95% CI: 0.74–0.94)].139 Notably, specific
patient subgroupsmay benefitmost from rigorous behaviouralmod-
ifications: young (age ,60 years) or old (age ≥75 years) patients,
patients with a sedentary lifestyle and/or a smoking habit, patients
with a low Mediterranean diet score and those who live alone.140
However, data from three EUROASPIRE surveys showed that
there was a clear need for more effective lifestyle management
among patients with previous coronary revascularization.141 The
authors rightfully stated that treatment of coronary artery disease
‘without addressing the underlying causes of the disease is futile;
we need to invest in prevention’.
Initiatives should be undertaken to increase the rate of prescribing
appropriate discharge medications and to emphasize the need for
long-termmedication compliance and lifestyle changes. In particular,
home-based programmes may be efficient and more acceptable to
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patients—with the additional benefit of lower costs.142 Such quality
improvement programmes canbe easily instated and couldpotential-
ly improve patient care significantly.
Decision-making
Despite the potential for further optimization of CABG outcomes,
PCI will remain an excellent alternative in specific patients. Evidence
suggests that there is overuse, underuse and inappropriate selection
of revascularization strategies.143 Inappropriate use and underuse
may partly explain the preferences expressed by patients,144 who
prefer less invasive techniques with minimized pain over the long-
term prospect of improved survival. In that respect, MIDCAB or
hybrid procedures may present an alternative, but often patients
are not even informed about the survival advantage with CABG.145
Naturally, if two treatments are considered to produce similar
results, patients will opt for the least invasive.
Reflecting on the current revascularization guidelines, recent trial
results and weighting risk–benefit ratios of (new) developments,
Figure 3 provides a proposal for a decision-tree for revascularization.
The myriad of treatment options emphasize the need for targeted
patient selection, and themix of surgical and interventional therapies
provides rationale for multidisciplinary Heart Team decision-making
to discuss all potential treatment options and obtain informed
consent. Clinical cardiologists, interventional cardiologists and
cardiovascular surgeons should convene on a regular basis to
recommend the most appropriate treatment strategy for individual
patients.143,146 The importance of a Heart Team was once more
stressed in the SYNTAX trial147 and was subsequently included in
the European andAmerican guidelines.3,148 Practicemay be different
across centres and countries, and a local protocol should be estab-
lished to define patient populations that are candidates for certain
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Table4 Trends in the use of secondary preventive medication and the difference between coronaryartery bypass grafting
and percutaneous coronary intervention
EUROASPIRE I
1995–96,
n 5 9 countries
EUROASPIRE II
1999–2000,
n 5 15 countries
EUROASPIRE III
2006–07,
n 5 22 countries
Antiplatelets (%)
CABG 87.9 86.8 92.9
PCI 89.4 90.0 94.9
D 21.5 23.2 22.0
Beta-blockers (%)
CABG 56.5 68.0 90.7
PCI 61.7 73.6 84.4
D 25.2 25.6 +6.3
Blood pressure-lowering drugs (%)
CABG 86.2 90.1 98.7
PCI 87.4 91.3 95.9
D 21.2 21.2 +2.8
Lipid-lowering drugs (%)
CABG 36.7 67.6 90.5
PCI 42.2 69.9 89.4
D 25.5 22.3 +1.1
Data from Kotseva et al.133
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
Figure2 Difference in secondarypreventionmeasures afterper-
cutaneous coronary intervention and coronary artery bypass graft-
ing. Data from Hiratzka et al. 134 ACE-I, angiotensin-converting
enzyme inhibitor; CABG, coronary artery bypass grafting; PCI, per-
cutaneous coronary intervention.
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therapies. The various pros and cons of surgical revascularization
strategies should then be considered by the Heart Team (Table 5).
Future studies
Rigorous evaluation of potential advancements remains crucial
before they are introduced on a wide scale. Even an extensive body
of evidence supporting some interventions is not necessarily suffi-
cient to provide evidence-based recommendations. This is exempli-
fied by the .60 randomized trials comparing off-pump with
on-pump surgery:13,30,35 a benefit of off-pump CABG has been sug-
gested in many studies that included different patient populations.
Nevertheless, the two latest and largest randomized trials that
included low- and high-risk patients found no difference between
the two treatment options.30,35
In contrast, data on some new therapeutic strategies remain
scarce, but the existing datamay demonstrate excellent safety and ef-
ficacy. Such results often represent outcomes from highly selected
patients treated by experienced surgeons in high-volume centres.
This introduces a bias; the generalizability of such results is limited
and caution is advised. An example of this is the evaluation of
TECAB procedures.
Percutaneous coronary intervention vs.
coronary artery bypass grafting studies
Continuous evaluation of PCI vs. CABG calls for a specific focus on
new developments in both interventions. For PCI patients, new
stents will become available and the use of fractional flow reserve
to assess the need and completeness of revascularization is empha-
sized.149,150 Equivalent data on FFR-guided CABG are scarce.151
Future studies should explore the use and differences of FFR-guided
revascularization between PCI and CABG.152 The impact of the
degree of ischaemia and viability on the outcomes of both CABG
and PCI in patients with stable angina is still under debate.
Whether image-guided revascularization that is based on a combin-
ation of functional and anatomical imaging—for example, position
emission tomography computed tomography (Figure 4)—can
improve the outcomes as compared with the traditional occuloste-
notic approach warrants further trials.
Figure 3 Proposal for a decision-tree for revascularization. Some of these recommendations have not yet been validated and still require rando-
mized evaluation. CABG, coronary artery bypass grafting; LAD, left anterior descending; LM, left main; MIDCAB,minimally invasive coronary artery
bypass; PCI, percutaneous coronary intervention.
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Traditionally, trials are limited to their internal validity, i.e. the
results are only applicable to the included patient cohort; large ‘real-
world’ registries are required to demonstrate whether trial results
are also applicable to the general population.10 Alternatively, an ‘all-
comers’ trial design with none to limited patient exclusion criteria
increases external validation, and presents amore balanced trade-off
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Table 5 Pros and cons of different surgical revascularization techniques
Conventional
CABG
Off-pump CABG MIDCAB TECAB Hybrid
revascularization
Lesions Multivessel disease
(+)
Multivessel disease (+) Isolated LAD stenosis
(+/2)
Multivessel disease (+) Multivessel disease (+)
Technical difficulty None (+) Moderate (+/2) Moderate (+/2) Difficult (2) Moderate (+/2)
Incision Sternotomy (2) Sternotomy (2) J-incision (+/2) Endoscopic (+) J-incision (+/2)
Cardiopulmonary bypass Yes (2) No (+) No (+) No (+) No (+)
Procedure time Short (+) Prolonged (+/2) Long (2) Long (2) Long (2)
Blood products Many (2) Less (+/2) Few (+) Few (+) Few (+)
Completeness of
revascularization
Complete (+) Complete (+) or
incomplete (+/2)
Complete (+) or
incomplete (+/2)
Complete (+) or
incomplete (+/2)
Complete (+)
Postoperative length of
stay
Long (2) Prolonged (+/2) Short (+) Short (+) Short (+)
Postoperative pain Yes (2) Yes (2) Yes (2) Less (+/2) Yes (2)
Recovery time Long (2) Long (2) Short (+) Short (+) Short (+)
Rate of stroke High (2) Less (+/2) Less (+/2) Less (+/2) Less (+/2)
Rate of repeat
revascularization
Good (+) Moderate (+/2) Good (+) Moderate (+/2) Moderate (+/2)
The various features are scored as following: in favour of the technique (+), reasonable in favour (+/2), detrimental for the technique (2).
CABG, coronary artery bypass grafting; LAD, left anterior descending; MIDCAB, minimally invasive coronary artery bypass.
Figure 4 Functional and anatomical imaging using position emission tomography computed tomography. Case: 70-year-old male had atypical
symptoms of three-vessel coronary artery disease for which he underwent stenting of the right coronary artery in 2012. Scan is positive for infer-
olateral wall ischaemia (purple). LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery.
Optimizing outcomes of CABG 2883
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 6 American and European guideline recommendations
Guidelines
American European
Off-pump CABG ‘In patients with preoperative renal dysfunction (creatinine clearance,60 mL/min), off-pump
CABG may be reasonable to reduce the risk of acute kidney injury’ IIb B
‘It is reasonable to consider off-pump CABG to reduce perioperative bleeding and allogeneic
blood transfusion’ IIa A
‘Off-pump CABG may be considered, rather than on-pump CABG for patients with
mild-to-moderate chronic kidney disease’ IIb B
MIDCAB No recommendation No recommendation
Hybrid
revascularization
‘Hybrid coronary revascularisation is reasonable in patients with 1 or more of the following:
limitations to traditional CABG, such as heavily calcified proximal aorta or poor target
vessels for CABG (but amenable to PCI); lack of suitable graft conduits; unfavourable LAD
artery for PCI (i.e. excessive vessel tortuosity or chronic total occlusion)’ IIa B
‘Hybrid coronary revascularization may be reasonable as an alternative to multivessel PCI or
CABG in an attempt to improve the overall risk–benefit ratio of the procedures’ IIb C
‘Hybrid procedure, defined as consecutive or combined surgical and interventional
revascularizationmay be considered in specific patient subsets at experienced centres’ IIb
B
Clampless/‘no
touch’
‘Patients with extensive disease of the ascending aorta pose a special challenge for on-pump
CABG; for these patients, cannulation or cross-clamping of the aorta may create an
unacceptably high risk of stroke. In such individuals, off-pump CABG in conjunction with
avoidance of manipulation of the ascending aorta (including placement of proximal
anastomoses) may be beneficial’ (no formal recommendation, no level of evidence)
No recommendation
Endoscopic vein
harvesting
No recommendation ‘Endoscopic vein-graft harvesting cannot be recommended at present as it has been
associated with vein-graft failure and adverse clinical outcomes’ (no formal
recommendation, no level of evidence)
Epiaortic scanning ‘Routine epiaortic ultrasound scanning is reasonable to evaluate the presence, location, and
severity of plaque in the ascending aorta to reduce the incidence of atheroembolic
complications’ IIa B
No recommendation
Graft flow
assessment
No recommendation ‘Graft evaluation is recommended before leaving the operating theatre’ I C
Arterial
revascularization
‘If possible, theLIMAshouldbeused tobypass theLADarterywhenbypass of theLADartery is
indicated’ I B
‘When anatomically and clinically suitable, use of a second IMA to graft the left circumflex or
right coronary artery (when critically stenosed and perusing LVmyocardium) is reasonable
to improve the likelihood of survival and to decrease reintervention’ IIa B
‘Complete arterial revascularizationmaybe reasonable inpatients≤60yearsof agewith fewor
no comorbidities’ IIb C
‘Arterial grafting to the LAD system is indicated’ I A
‘Complete revascularization with arterial grafting to non-LAD coronary systems is indicated
in patients with reasonable life expectancy’ I A
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between internal and external validation.153 Furthermore, reporting
the experience of centres and operators will also contribute to the
internal and external validity of trial results: superior outcomes in
experienced centres as opposed to inexperienced centres unveils
limited external validity and should restrict one from over-
extrapolating trial results to real-world clinical settings.
In the SYNTAX trial a new angiographic scorewas validated—the
SYNTAX score—for grading the complexity of coronary artery
disease.154This score appears tobe averypromising tool fordeciding
if PCI or CABG would be preferable. Use of the score is therefore
recommended for decision-making. Recently, the SYNTAX II score
was introduced and showed an improvement in guiding decision-
making.155 Yet, further validation of these hypothesis-generating
data is needed and future studies should provide a larger body of evi-
dence about the SYNTAX (II) score.
Pharmacological management of patients after PCI and CABG
differs significantly and has an impact on long-term results. It would
be interesting to see the results of PCI and CABG if the pharmaco-
logical management and treatment adherence after PCI and CABG
would be identical.
Discussion
Broadening indications for and increasing use of PCI calls for more
focus on the optimization of short- and long-term outcomes after
CABG. Expanding the use of lesser invasive techniques may per-
suade patients to accept surgery as the preferable treatment
option. Particularly studies comparing PCI with CABG require the
most optimal surgical revascularization strategy to show superiority
over PCI. Arterial revascularization with minimized aortic manipula-
tion and intra-operative graft flow measurement is a relatively easy
way to improve outcomes.
Adoption rates of new techniques have been low, despite all
advances. This may be due to: (i) the familiarity that surgeons have
with existing techniques, a reluctance to change and the willingness
to go through the learning curve typical for a new technique, (ii)
the more demanding nature of some technical advances, (iii) compli-
cations related to the use of a new technique and/or device, (iv) time-
consuming steps that may have to be carried out during the proced-
ure, and (v) logistic reasons with regard to the need for additional
equipment, planning and sterility. Particularly when the presumed
benefits with new techniques are not yet clearly proven, these
factors play a major role in maintaining existing protocols.
However, the benefit of advancements will often become evident
when overcoming the learning curve.On the other hand, some tech-
niques will always be time-consuming and reserved for highly specia-
lized centres.
Guidelines
One explanation for the underuse of new techniques and secondary
preventionmeasuresmay be the lackof data supporting their benefit.
This calls for large registries and randomized trials to provide add-
itional rigorous evaluation of, in particular, MIDCAB, hybrid revascu-
larization, epiaortic scanning and graft flow measurement. Another
reason for lack of widespread implementation and geographic varia-
tions may be the differing recommendations of the American and
European guidelines concerning their use (Table 6). This is illustrated
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by recommendations for epiaortic scanning and graft flow assess-
ment. The current European ESC/EACTS revascularization guide-
lines include a class 1C recommendation for intra-operative graft
flow assessment 3 and the American guidelines state that ‘epiaortic
ultrasound is reasonable to evaluate. . .’, which translates to a class
IIa B recommendation.148 However, the American guidelines do
not include a recommendation for graft flow assessment, while the
European guidelines lack a recommendation for epiaortic scanning.
Patient, cost, and market considerations
Adoption of minimally invasive techniques that result in lower post-
operative complications and reduced length of stay will significantly
improve patient satisfaction, and raise patients’ willingness to
undergo CABG as opposed to PCI. On the background of the issue
of rising healthcare expenditures, these improvements may also
help reduce overall costs.
Continued optimization of short- and long-term outcomes of
CABG will reduce costs for health insurance providers who may
therefore favour adoption of new techniques associated with
shorter initial in-hospital stays, reduced complication rates and
fewer repeat revascularizations. In addition, pay for performance is
increasingly instated.156 This system provides additional incentives
to innovate and improve outcomes.
Containing costs to both health insurance providers and societies
may in somehealthcare systems require a reductionof the numberof
centres performing CABG. Innovation and integrating technological
advances into everyday clinical practice may be rewarded by certifi-
cation as a centre of excellence, by continued issuance of a practice
licence and by more patient referrals. Implementation of the Heart
Teamdecision-making processmay furthermore strengthen the pos-
ition of a centre. This approach highlights the centre’s collaborative
environment between specialties, which is appreciated by
patients.143 Theremay also be major cost implications by eradicating
suboptimal treatment: healthcare costs will be contained as rates of
adverse events requiring rehospitalization and additional procedures
are reduced.
Conclusion
Outcomes after surgical revascularization have the potential to
improve beyond the level achieved during recent decades
(Figure 5). However, to facilitate these improvements, surgeons
need to be willing to adopt new techniques that increase procedural
safety, patient satisfaction, and long-term survival. To achieve these
goals, guidelines should be conclusive about recommending certain
techniques and provide guidance for their use. Future trials will
need to provide sufficient evidence for such recommendations by
focussing on specific areas where optimal therapy has yet to be
substantiated.
Conflict of interest: none declared.
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